Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of “Hold” from Brokerages

Shares of Invivyd, Inc. (NASDAQ:IVVD) have earned a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.00.

IVVD has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Tuesday, June 9th. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IVVD. OMERS ADMINISTRATION Corp raised its stake in shares of Invivyd by 9.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock worth $139,000 after purchasing an additional 8,800 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Invivyd by 54.3% in the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after purchasing an additional 9,568 shares during the last quarter. Courier Capital LLC purchased a new position in shares of Invivyd in the fourth quarter worth about $25,000. Bronte Capital Management Pty Ltd. purchased a new position in shares of Invivyd in the fourth quarter worth about $27,000. Finally, DRW Securities LLC purchased a new position in shares of Invivyd in the fourth quarter worth about $27,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Price Performance

Shares of IVVD stock opened at $0.97 on Friday. Invivyd has a 1-year low of $0.48 and a 1-year high of $3.07. The stock’s 50-day moving average is $1.28 and its 200 day moving average is $1.72. The company has a market cap of $285.74 million, a P/E ratio of -3.13 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The company had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. On average, analysts anticipate that Invivyd will post -0.5 EPS for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.